Mechanism Study of Kang’ai Fangyi Tablets in Inhibiting Angiogenesis of 4T1 Breast Cancer
10.13359/j.cnki.gzxbtcm.2015.05.018
- VernacularTitle:抗癌防移片抑制4T1乳腺癌血管生成的机制研究
- Author:
Chao HOU
;
Zhixi HU
- Publication Type:Journal Article
- Keywords:
Kang’ai Fangyi Tablets/pharmacology;
Breast cancer/TCD therapy;
Anti-angiogenesis;
Breast cancer cells/pathology;
Disease models,animal;
Mice
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2015;(5):861-864
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the angiogenesis-inhibitory mechanism of Kang’ai Fangyi Tablets ( KFT) , a Chinese compound recipe with the action of inhibiting cancer metastasis, for 4T1 breast cancer. Methods BALB/c mice were divided into blank control group, model group, Cytoxan ( CTX, 0.04 g·kg-1·d-1) group, and KFT ( 5.2 g·kg-1·d-1) group. Mice model of 4T1 breast cancer was established. Except that the blank control group and model group were given the saline, the mice in the medication groups were given the corresponding medicine. After medication for 4 weeks, the mice were executed, and then we calculated the mass of tumor, the inhibition rate of tumor mass, and the number of lung metastatic nodules. The number of microvessel and expression of vascular endothelial growth factor (VEGF) were measured by immunohistochemical method. Results Compared with the model group, mice tumor mass was decreased ( P<0.05) , the number of pulmonary metastatic nodules was reduced ( P<0.05) , and the number of tumor microvessel and VEGF expression in the isolated tumor mass showed the decreasing trend in KFT group. Conclusion KFT can inhibit 4T1 breast cancer growth and metastasis by reducing the tumor microvessel formation and by affecting the expression of VEGF.
